SPHK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Besides combinational treatment, C6-ceramide and SphK1 inhibitor independently induce apoptosis in imatinib-resistant CML cell lines KBM5 and LAMA84s, respectively [59, 152].